Eunyoung Suh

TL;DR: Rivaroxaban, given to medical patients for 45 days after hospital discharge, was not associated with a significantly lower risk of symptomatic venous thromboembolism and death due to venousThromboprophylaxis than placebo.

TL;DR: In the ROCKET AF trial, rivaroxaban increased GI bleeding compared with warfarin, illustrating the need for minimizing modifiable risk factors for GI bleeding in patients on oral anticoagulation.

TL;DR: The MARINER study is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, for preventing symptomatic VTE in high-risk medical patients.

TL;DR: The benefit risk profile was favorable in this subpopulation treated for 35 days, with the number of patients needed to treat ranging from 55 to 481 and number needed to harm from 455 to 1067 for all pairwise evaluations.

TL;DR: The PREVENT-HD trial as discussed by the authors is a double-blind, placebo-controlled, pragmatic, event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events, hospitalization and death.